Serdemetan

Research use only, not for human use.

Serdemetan (JNJ 26854165) is a novel anticancer agent that inhibits the function of the E3 ligase HDM2.

Serdemetan (JNJ 26854165) is a novel anticancer agent that inhibits the function of the E3 ligase HDM2, dose-dependently inhibits proliferation in both wild-type and mutant p53 cell lines with IC50 of 0.25-3 uM; induces p53-mediated apoptosis in acute leukemia cells with wild-type p53, accelerates the proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53, induces S-phase delay and upregulates E2F1 expression in p53 mutant cells; demonstrates radiosensitizing activity in vitro and in tumor xenografts.Lung Cancer Phase 1 Discontinued.

——

——

JNJ 26854165 | JNJ26854165 | JNJ-26854165

Apoptosis

MDM2-p53

HDM2|Mdm2|p53

Cancer

Lung Cancer

881202-45-5

328.4103

C21H20N4

>98% (HPLC)

10 mM in DMSO

C1(NCCC2=CNC3=C2C=CC=C3)=CC=C(NC4=CC=NC=C4)C=C1

1,4-Benzenediamine, N1-[2-(1H-indol-3-yl)ethyl]-N4-4-pyridinyl-

(-20℃)

With Ice Pack

≥ 2 years